All In Biotech

Drug Trial Radar · NCT05063162

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

113

Actual

Start

Feb 2, 2022

Primary completion

May 6, 2027

Study completion Jul 1, 2027

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Sep 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).

Conditions

  • Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

Interventions

  • RozanolixizumabDrug

    * Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive pre-specified doses of rozanolixizumab.

  • PlaceboOther

    * Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment PeriodTime frame: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
  2. For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment PeriodTime frame: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
  3. For Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment PeriodTime frame: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)

Locations

55 sites in 20 countries. Site status is shown where the registry gives one.

  • Mog001 50297

    Scottsdale, Arizona

  • Mog001 50450

    Palo Alto, California

  • Mog001 50101

    Aurora, Colorado

  • Mog001 50553

    Washington D.C., District of Columbia

  • Mog001 50308

    Tampa, Florida

  • Mog001 50472

    Peoria, Illinois

  • Mog001 50552

    Baltimore, Maryland

  • Mog001 50243

    Boston, Massachusetts

  • Mog001 50104

    Rochester, Minnesota

  • Mog001 50568

    San Antonio, Texas

  • Mog001 50473

    Salt Lake City, Utah

  • Mog001 30022

    Melbourne, Australia

  • Mog001 40185

    Ghent, Belgium

  • Mog001 60033

    Porto Alegre, Brazil

  • Mog001 40195

    Hradec Králové, Czechia

  • Mog001 40721

    Teplice, Czechia

  • Mog001 40170

    Strasbourg, France

  • Mog001 40140

    Göttingen, Germany

  • Mog001 40177

    Münster, Germany

  • Mog001 40850

    Athens, Greece

  • Mog001 40146

    Pavia, Italy

  • Mog001 40629

    Roma, Italy

  • Mog001 40646

    Verona, Italy

  • Mog001 20068

    Chiba, Japan

  • Mog001 20307

    Isehara, Japan

  • Mog001 20049

    Kitakyushu-shi, Japan

  • Mog001 20143

    Kodaira, Japan

  • Mog001 20223

    Koriyama-shi, Japan

  • Mog001 20224

    Sendai, Japan

  • Mog001 20227

    Sendai, Japan

  • Mog001 20070

    Shinjuku-ku, Japan

  • Mog001 20032

    Suita-shi, Japan

  • Mog001 50486

    Culiacán, Mexico

  • Mog001 50485

    Mexico City, Mexico

  • Mog001 40840

    Bydgoszcz, Poland

  • Mog001 40485

    Coimbra, Portugal

  • Mog001 40669

    Porto, Portugal

  • Mog001 20226

    Goyang-si, South Korea

  • Mog001 40267

    Barcelona, Spain

  • Mog001 40161

    Madrid, Spain

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.